Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Viral Hepatitis

Quick Links

Veterans Crisis Line Badge
My healthevet badge

Supplemental Table 1: Treatment Monitoring Guidelines for Patients on Peginterferon-Ribavirin

for Health Care Providers

Supplemental Table 1: Treatment Monitoring Guidelines for Patients on Peginterferon-Ribavirin plus or minus Protease Inhibitor (Boceprevir or Telaprevir)

Back to Tables

Week

*Intervals may need to be increased based on patient tolerance and response to treatment in patients with significant declines in blood counts, renal insufficiency, diabetes, cirrhosis or other indications.

**Recommended for all patients at baseline and periodically during antiviral treatment in patients with diabetes, hypertension or as needed for visual complaints.

Necessary02481224Every 4-weeks ThereafterEnd-of-Treatment24 weeks Post-treatment
HCV RNA Follow Algorithm for additional timepoints
CBC with differential√*
Liver function tests√*
Psychiatric/Substance Use Screening√*
Renal panel *
Glucose *
TSH *
Uric acid (if on telaprevir)*
Pregnancy test
Recommended
Fundoscopic Exam**
Urine Toxicology Screen